Trial
NCT02966587
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)
Condition
Castration Levels of Testosterone
Intervention
Durvalumab
Why stopped
Withdrawn prior to opening to enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-17